Presentation is loading. Please wait.

Presentation is loading. Please wait.

Roh Yanagida, MD, PhD, Lawrence S. C. Czer, MD, Nancy L

Published byBenedict Bryan Modified over 5 years ago

Similar presentations

Presentation on theme: "Roh Yanagida, MD, PhD, Lawrence S. C. Czer, MD, Nancy L"— Presentation transcript:

1 Impact of Virtual Cross Match on Waiting Times for Heart Transplantation 
Roh Yanagida, MD, PhD, Lawrence S.C. Czer, MD, Nancy L. Reinsmoen, PhD, Kai Cao, MD, Matthew Rafiei, BS, Michele A. De Robertis, RN, James Mirocha, MS, Robert M. Kass, MD, Jon A. Kobashigawa, MD, Alfredo Trento, MD  The Annals of Thoracic Surgery  Volume 92, Issue 6, Pages (December 2011) DOI: /j.athoracsur Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Waiting time for patients before (A) and after (B) VC. No patients waited longer than a year after VC. (PRA = panel reactive antibody; preVC = prospective cross match; VC = virtual cross match.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Kaplan-Meier estimates of survival for sensitized and nonsensitized patients before and after VC. (PRA = panel reactive antibody; preVC = prospective cross match; VC = virtual cross match.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Kaplan-Meier estimates of survival by sensitized status. (PRA = panel reactive antibody.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Kaplan-Meier estimates of survival before and after VC. (preVC = prospective cross match; VC = virtual cross match.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

6 Fig 5 Kaplan-Meier estimates of freedom from 3A (2R) cellular rejection for sensitized and nonsensitized patients before and after virtual cross match. (PRA = panel reactive antibody; preVC = prospective cross match; VC = virtual cross match.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

7 Fig 6 Kaplan-Meier estimates of freedom from antibody-mediated rejection for sensitized and nonsensitized patients before and after virtual cross match. (PRA = panel reactive antibody; preVC = prospective cross match; VC = virtual cross match.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

8 Fig 7 Donor geographic area outside regional organ procurement organization (OPO) (OneLegacy). Relative size of the dot depicts the number of donors from each site. Shaded area corresponds to the area covered by the regional OPO. (preVC = prospective cross match; VC = virtual cross match.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Roh Yanagida, MD, PhD, Lawrence S. C. Czer, MD, Nancy L"

Similar presentations

Changes in Risk Profile Over Time in the Population of a Pediatric Heart Transplant Program Olaf Reinhartz, MD, Katsuhide Maeda, MD, Bruce A. Reitz, MD,

Changes in Risk Profile Over Time in the Population of a Pediatric Heart Transplant Program Olaf Reinhartz, MD, Katsuhide Maeda, MD, Bruce A. Reitz, MD,
Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C.

Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C.
Serum C-Reactive Protein as a Predictor of Morbidity and Mortality in Intensive Care Unit Patients After Esophagectomy  Michel E. van Genderen, BS, Alexandre.

Serum C-Reactive Protein as a Predictor of Morbidity and Mortality in Intensive Care Unit Patients After Esophagectomy  Michel E. van Genderen, BS, Alexandre.
High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients  Danielle K. Farrington, MD, Patrick D. Kilgo,

High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients  Danielle K. Farrington, MD, Patrick D. Kilgo,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.
Niv Ad, MD, Linda Henry, PhD, RN, Deborah J. Shuman, BS, Sari D

Niv Ad, MD, Linda Henry, PhD, RN, Deborah J. Shuman, BS, Sari D
Outcomes of Reintervention on the Autograft After Ross Procedure

Outcomes of Reintervention on the Autograft After Ross Procedure
Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M

Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M
Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?  Tirone E. David, MD, Susan Armstrong, MS,

Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?  Tirone E. David, MD, Susan Armstrong, MS,
Danny Ramzy, MD, PhD, Alfredo Trento, MD, Wen Cheng, MD, Michele A

Danny Ramzy, MD, PhD, Alfredo Trento, MD, Wen Cheng, MD, Michele A
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Risk Factors Associated With Reoperation and Mortality in 252 Patients After Aortic Valve Replacement for Congenitally Bicuspid Aortic Valve Disease 

Risk Factors Associated With Reoperation and Mortality in 252 Patients After Aortic Valve Replacement for Congenitally Bicuspid Aortic Valve Disease 
Long-Term Consequences of Postoperative Heart Failure After Surgery for Aortic Stenosis Compared With Coronary Surgery  Farkas B. Vánky, MD, PhD, Erik.

Long-Term Consequences of Postoperative Heart Failure After Surgery for Aortic Stenosis Compared With Coronary Surgery  Farkas B. Vánky, MD, PhD, Erik.
Spinal Cord Stimulation for Patients With Refractory Angina and Previous Coronary Surgery  Elisabetta Lapenna, MD, Dino Rapati, MD, Paola Cardano, MS,

Spinal Cord Stimulation for Patients With Refractory Angina and Previous Coronary Surgery  Elisabetta Lapenna, MD, Dino Rapati, MD, Paola Cardano, MS,
Michael E. Halkos, MD, Patrick Kilgo, MS, Omar M

Michael E. Halkos, MD, Patrick Kilgo, MS, Omar M
James R. Edgerton, MD, Morley A

James R. Edgerton, MD, Morley A
ABO-Identical Blood Group Matching Has No Survival Benefit for AB Heart Transplant Recipients  Henrik Bergenfeldt, MD, Peter Höglund, MD, PhD, Bodil Andersson,

ABO-Identical Blood Group Matching Has No Survival Benefit for AB Heart Transplant Recipients  Henrik Bergenfeldt, MD, Peter Höglund, MD, PhD, Bodil Andersson,
Comparing Long-Term Survival Between Patients Undergoing Off-Pump and On-Pump Coronary Artery Bypass Graft Operations  Giovanni Filardo, PhD, MPH, Paul.

Comparing Long-Term Survival Between Patients Undergoing Off-Pump and On-Pump Coronary Artery Bypass Graft Operations  Giovanni Filardo, PhD, MPH, Paul.
Biventricular Conversion After Single Ventricle Palliation in Patients With Small Left Heart Structures: Short-Term Outcomes  Brian T. Kalish, MD, Puja.

Biventricular Conversion After Single Ventricle Palliation in Patients With Small Left Heart Structures: Short-Term Outcomes  Brian T. Kalish, MD, Puja.

Similar presentations

Ads by Google